Skip to Content
Merck

PLGA-based nanoparticles as cancer drug delivery systems.

Asian Pacific journal of cancer prevention : APJCP (2014-02-27)
Fatemeh Sadat Tabatabaei Mirakabad, Kazem Nejati-Koshki, Abolfazl Akbarzadeh, Mohammad Rahmati Yamchi, Mortaza Milani, Nosratollah Zarghami, Vahideh Zeighamian, Amirbahman Rahimzadeh, Somayeh Alimohammadi, Younes Hanifehpour, Sang Woo Joo
ABSTRACT

Poly (lactic-co-glycolic acid) (PLGA) is one of the most effective biodegradable polymeric nanoparticles (NPs). It has been approved by the US FDA to use in drug delivery systems due to controlled and sustained- release properties, low toxicity, and biocompatibility with tissue and cells. In the present review, the structure and properties of PLGA copolymers synthesized by ring-opening polymerization of DL-lactide and glicolide were characterized using 1H nuclear magnetic resonance spectroscopy, gel permeation chromatography, Fourier transform infrared spectroscopy and differential scanning calorimetry. Methods of preparation and characterization, various surface modifications, encapsulation of diverse anticancer drugs, active or passive tumor targeting and different release mechanisms of PLGA nanoparticles are discussed. Increasing experience in the application of PLGA nanoparticles has provided a promising future for use of these nanoparticles in cancer treatment, with high efficacy and few side effects.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
NanoFabTx PEG-PLGA drug formulation screening kit, for synthesis of PEGylated nanoparticles
Sigma-Aldrich
NanoFabTx PLGA-nano, for synthesis of 100 and 200 nm particles